Mostrar el registro sencillo del ítem

dc.creatorMangera, A.en
dc.creatorAndersson, K. E.en
dc.creatorApostolidis, A.en
dc.creatorChapple, C.en
dc.creatorDasgupta, P.en
dc.creatorGiannantoni, A.en
dc.creatorGravas, S.en
dc.creatorMadersbacher, S.en
dc.date.accessioned2015-11-23T10:38:39Z
dc.date.available2015-11-23T10:38:39Z
dc.date.issued2011
dc.identifier10.1016/j.eururo.2011.07.001
dc.identifier.issn0302-2838
dc.identifier.urihttp://hdl.handle.net/11615/30613
dc.description.abstractContext: The use of botulinum toxin A (BoNTA) in the treatment of lower urinary tract dysfunction has expanded in recent years and the off-licence usage list includes neurogenic detrusor overactivity (NDO), idiopathic detrusor overactivity (IDO), painful bladder syndrome (PBS), and lower urinary tract symptoms resulting from bladder outflow obstruction (BOO) or detrusor sphincter dyssynergia (DSD). There are two commonly used preparations of BoNTA: Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Objective: To compare the reported outcomes of onabotulinumtoxinA and abobotulinumtoxinA in the treatment of NDO, IDO, PBS, DSD, and BOO for adults and children. Evidence acquisition: We performed a systematic review of the published literature on PubMed, Scopus, and Embase in the English language reporting on outcomes of both BoNTA preparations. Review articles and series with < 10 cases were excluded. The articles were graded for level of evidence and conclusions drawn separately for data with higher-level evidence. Evidence synthesis: There is high-level evidence for the use of onabotulinumtoxinA and abobotulinumtoxinA in adults with NDO but only for abobotulinumtoxinA in children with NDO. Only onabotulinumtoxinA has level 1 evidence supporting its use in IDO, BOO, DSD, and PBS/interstitial cystitis. Conclusions: We identified good-quality studies that evaluated onabotulinumtoxinA for all the indications described above in adults; such was not the case with abobotulinumtoxinA. Although this does not imply that onabotulinumtoxinA is more effective than abobotulinumtoxinA, it should be a consideration when counselling patients on the use of botulinum toxin in urologic applications. The two preparations should not be used interchangeably, either in terms of predicting outcome or in determining doses to be used. (C) 2011 European Association of Urology. Published by Elsevier B. V. All rights reserved.en
dc.source.uri<Go to ISI>://WOS:000294304100032
dc.subjectAbobotulinumtoxinAen
dc.subjectBladder outflow obstructionen
dc.subjectBotoxen
dc.subjectBotulinum toxinen
dc.subjectDetrusor sphincter dyssynergiaen
dc.subjectDysporten
dc.subjectIdiopathic detrusoren
dc.subjectoveractivityen
dc.subjectNeurogenic detrusor overactivityen
dc.subjectOnabotulinumtoxinAen
dc.subjectPainful bladder syndromeen
dc.subjectNEUROGENIC DETRUSOR OVERACTIVITYen
dc.subjectBENIGN PROSTATIC HYPERPLASIAen
dc.subjectNEUROTOXIN TYPE-Aen
dc.subjectQUALITY-OF-LIFEen
dc.subjectCYSTITIS/PAINFUL BLADDER SYNDROMEen
dc.subjectMULTIPLE-SCLEROSIS PATIENTSen
dc.subjectPLACEBO-CONTROLLED TRIALen
dc.subjectSPINAL-CORDen
dc.subjectDISEASEen
dc.subjectSPHINCTER DYSSYNERGIAen
dc.subjectDOUBLE-BLINDen
dc.subjectUrology & Nephrologyen
dc.titleContemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)en
dc.typejournalArticleen


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem